CN103830684B - One treats menorrheal pharmaceutical composition and application thereof - Google Patents
One treats menorrheal pharmaceutical composition and application thereof Download PDFInfo
- Publication number
- CN103830684B CN103830684B CN201410108684.7A CN201410108684A CN103830684B CN 103830684 B CN103830684 B CN 103830684B CN 201410108684 A CN201410108684 A CN 201410108684A CN 103830684 B CN103830684 B CN 103830684B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- herba
- cortex
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to one and treat menorrheal pharmaceutical composition, it is made up of following bulk drugs: Folium fici lacoris, Herba bromi japonici, Herba saniculae orthacanthae, the Radix Angelicae Dahuricae, Radix Bupleuri, Semen Ziziphi Spinosae, Herba menyanthis, Fructus Arctii, Spica Prunellae, Herba Cleisostomatis scolopendrifolii, Radix Saposhnikoviae, Bulbus Lilii, Cortex celtis bungeanae (Cortex seu Caulis Celtis Bungeane), Ramulus Cinnamomi, Rhizoma Atractylodis, Radix et Rhizoma Smilacis Ripariae, Fructus Ligustri Lucidi, Radix Achyranthis Bidentatae, Fructus Cnidii, Rhizoma Coptidis, the Radix Paeoniae Alba, JIANCAO, Radix Arnebiae (Radix Lithospermi), the Cortex Eucommiae, Herba Lycopodii, the Rhizoma Atractylodis Macrocephalae, Radix Curcumae and Radix Codonopsis.The reasonable recipe of the menorrheal pharmaceutical composition for the treatment of of the present invention, has determined curative effect, safe ready, has no side effect, cheap feature.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to one and treat menorrheal pharmaceutical composition and application thereof.
Background technology
Menorrheal definition is that in continuous several menstrual cycle, BTB amount is many, but menstruation interval time and bleeding time are all regular, without the unexpected increase of intermenstrual bleeding, postcoital bleeding or menses.There is the class in ovulation type dysfunctional uterine bleeding in system.
Summary of the invention
The object of this invention is to provide one and treat menorrheal pharmaceutical composition.
In order to realize object of the present invention, the invention provides one and treat menorrheal pharmaceutical composition, it is made up by weight of following bulk drugs: Folium fici lacoris 50-100 part, Herba bromi japonici 50-100 part, Herba saniculae orthacanthae 50-100 part, Radix Angelicae Dahuricae 20-50 part, Radix Bupleuri 20-50 part, Semen Ziziphi Spinosae 20-50 part, Herba menyanthis 20-50 part, Radix Aconiti Lateralis Preparata 20-40 part, Fructus Arctii 20-50 part, Spica Prunellae 20-50 part, Herba Cleisostomatis scolopendrifolii 10-30 part, Radix Saposhnikoviae 20-50 part, Bulbus Lilii 20-50 part, Cortex celtis bungeanae (Cortex seu Caulis Celtis Bungeane) 20-40 part, Ramulus Cinnamomi 20-40 part, Rhizoma Atractylodis 10-30 part, Radix et Rhizoma Smilacis Ripariae 10-30 part, Fructus Ligustri Lucidi 20-40 part, Radix Achyranthis Bidentatae 10-30 part, Fructus Cnidii 1-30 part, Rhizoma Coptidis 1-20 part, Radix Paeoniae Alba 1-30 part, JIANCAO 1-10 part, Radix Arnebiae (Radix Lithospermi) 1-10 part, Cortex Eucommiae 1-30 part, Herba Lycopodii 1-10 part, Rhizoma Atractylodis Macrocephalae 1-10 part, Radix Curcumae 1-10 part and Radix Codonopsis 1-10 part.
Preferably, the menorrheal pharmaceutical composition for the treatment of of the present invention is made up by weight of following bulk drugs: Folium fici lacoris (Classification system Ficusvirens) 55 parts, Herba bromi japonici (Classification system BromusjaponicusThunb.exMurr.) 70 parts, Herba saniculae orthacanthae (base was the herb of samphire straight thrust sanicle originally) 60 parts, the Radix Angelicae Dahuricae 40 parts, Radix Bupleuri 35 parts, Semen Ziziphi Spinosae 50 parts, Herba menyanthis (Classification system Menyantehestrifoliata) 30 parts, Radix Aconiti Lateralis Preparata 25 parts, Fructus Arctii 45 parts, Spica Prunellae 30 parts, Herba Cleisostomatis scolopendrifolii (Classification system Cleisostomascolopendrifolium) 20 parts, Radix Saposhnikoviae 40 parts, Bulbus Lilii 40 parts, Cortex celtis bungeanae (Cortex seu Caulis Celtis Bungeane) (Classification system CeltisbungeanaBl.) 30 parts, Ramulus Cinnamomi 25 parts, Rhizoma Atractylodis 15 parts, Radix et Rhizoma Smilacis Ripariae (Classification system HeterosmilaxchinensisWang) 15 parts, Fructus Ligustri Lucidi 25 parts, Radix Achyranthis Bidentatae 20 parts, Fructus Cnidii 10 parts, Rhizoma Coptidis 5 parts, the Radix Paeoniae Alba 10 parts, JIANCAO (Classification system Chloranthusfortunei(A.Gray) SolmsLamb.) 5 parts, Radix Arnebiae (Radix Lithospermi) 5 parts, the Cortex Eucommiae 10 parts, Herba Lycopodii 2 parts, the Rhizoma Atractylodis Macrocephalae 5 parts, Radix Curcumae 5 parts and Radix Codonopsis 2 parts.
More preferably, described pharmaceutical composition can be tablet, dispersible tablet, disintegrating tablet, rapidly dissolving tablet, enteric coatel tablets, lotion or decoction.
The present invention also provides the application of pharmaceutical composition in the menorrheal medicine of preparation treatment, described pharmaceutical composition is made up by weight of following bulk drugs: Folium fici lacoris 50-100 part, Herba bromi japonici 50-100 part, Herba saniculae orthacanthae 50-100 part, Radix Angelicae Dahuricae 20-50 part, Radix Bupleuri 20-50 part, Semen Ziziphi Spinosae 20-50 part, Herba menyanthis 20-50 part, Radix Aconiti Lateralis Preparata 20-40 part, Fructus Arctii 20-50 part, Spica Prunellae 20-50 part, Herba Cleisostomatis scolopendrifolii 10-30 part, Radix Saposhnikoviae 20-50 part, Bulbus Lilii 20-50 part, Cortex celtis bungeanae (Cortex seu Caulis Celtis Bungeane) 20-40 part, Ramulus Cinnamomi 20-40 part, Rhizoma Atractylodis 10-30 part, Radix et Rhizoma Smilacis Ripariae 10-30 part, Fructus Ligustri Lucidi 20-40 part, Radix Achyranthis Bidentatae 10-30 part, Fructus Cnidii 1-30 part, Rhizoma Coptidis 1-20 part, Radix Paeoniae Alba 1-30 part, JIANCAO 1-10 part, Radix Arnebiae (Radix Lithospermi) 1-10 part, Cortex Eucommiae 1-30 part, Herba Lycopodii 1-10 part, Rhizoma Atractylodis Macrocephalae 1-10 part, Radix Curcumae 1-10 part and Radix Codonopsis 1-10 part.
Preferably, described pharmaceutical composition is made up by weight of following bulk drugs: Folium fici lacoris 55 parts, Herba bromi japonici 70 parts, Herba saniculae orthacanthae 60 parts, the Radix Angelicae Dahuricae 40 parts, Radix Bupleuri 35 parts, Semen Ziziphi Spinosae 50 parts, Herba menyanthis 30 parts, Radix Aconiti Lateralis Preparata 25 parts, Fructus Arctii 45 parts, Spica Prunellae 30 parts, Herba Cleisostomatis scolopendrifolii 20 parts, Radix Saposhnikoviae 40 parts, Bulbus Lilii 40 parts, Cortex celtis bungeanae (Cortex seu Caulis Celtis Bungeane) 30 parts, Ramulus Cinnamomi 25 parts, Rhizoma Atractylodis 15 parts, Radix et Rhizoma Smilacis Ripariae 15 parts, Fructus Ligustri Lucidi 25 parts, Radix Achyranthis Bidentatae 20 parts, Fructus Cnidii 10 parts, Rhizoma Coptidis 5 parts, the Radix Paeoniae Alba 10 parts, JIANCAO 5 parts, Radix Arnebiae (Radix Lithospermi) 5 parts, the Cortex Eucommiae 10 parts, Herba Lycopodii 2 parts, the Rhizoma Atractylodis Macrocephalae 5 parts, Radix Curcumae 5 parts and Radix Codonopsis 2 parts.
Generally acknowledged that " organic conception ", " determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs ", " compound recipe use ", " compound compatibility medication is as used military forces " are the traditional Chinese medical science the most effective most scientific several large advantages at present, wherein " compound compatibility medication is as used military forces " is the original theory of Chinese medicine of very science.The tight compatibility that in traditional Chinese medical science prescription, each medicine is all linked with one another as arrayed troops for battle is that it is better than the effective means of Western medicine formula.Tcm prescription theory is thought, each prescription, not only need to select the appropriate compatibility of suitable medicine according to etiology and pathogenesis, also should meet the basic structure of prescription simultaneously, the i.e. prescription compatibility theory of " monarch, minister, help, make ", the prescription compatibility of so-called " monarch, minister, help, make " is exactly that it is based upon the scientific matching on the comprehensive judgement basis of disease pathogenesis.In medical side by too many levels, Mutiple Targets Integrate adjustment biological mechanism, can to obtain than Western medicine more lastingly, the more therapeutic effect that has no side effect of green natural, and this curative effect be based upon the above-mentioned traditional Chinese medical science tradition original theory accurate instruction on, the present invention just have followed this principle.
In compositions of the present invention: Folium fici lacoris, Herba bromi japonici and Herba saniculae orthacanthae are monarch drug; The Radix Angelicae Dahuricae, Radix Bupleuri, Semen Ziziphi Spinosae, Herba menyanthis, Radix Aconiti Lateralis Preparata, Fructus Arctii, Spica Prunellae, Herba Cleisostomatis scolopendrifolii, Radix Saposhnikoviae, Bulbus Lilii and Cortex celtis bungeanae (Cortex seu Caulis Celtis Bungeane) are ministerial drug; Ramulus Cinnamomi, Rhizoma Atractylodis, Radix et Rhizoma Smilacis Ripariae, Fructus Ligustri Lucidi, Radix Achyranthis Bidentatae, Fructus Cnidii, Rhizoma Coptidis and the Radix Paeoniae Alba are adjuvant drug; JIANCAO, Radix Arnebiae (Radix Lithospermi), the Cortex Eucommiae, Herba Lycopodii, the Rhizoma Atractylodis Macrocephalae, Radix Curcumae and Radix Codonopsis are for making medicine.All medicines are harmonious in the present invention, reasonable recipe, have determined curative effect, safe ready, have no side effect, cheap feature.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Unless otherwise stated, the percent in the present invention is percetage by weight.
Embodiment lotion of the present invention
Get Folium fici lacoris 550 grams, Herba bromi japonici 700 grams, Herba saniculae orthacanthae 600 grams, the Radix Angelicae Dahuricae 400 grams, Radix Bupleuri 350 grams, Semen Ziziphi Spinosae 500 grams, Herba menyanthis 300 grams, Radix Aconiti Lateralis Preparata 250 grams, Fructus Arctii 450 grams, Spica Prunellae 300 grams, Herba Cleisostomatis scolopendrifolii 200 grams, Radix Saposhnikoviae 400 grams, Bulbus Lilii 400 grams, Cortex celtis bungeanae (Cortex seu Caulis Celtis Bungeane) 300 grams, Ramulus Cinnamomi 250 grams, Rhizoma Atractylodis 150 grams, Radix et Rhizoma Smilacis Ripariae 150 grams, Fructus Ligustri Lucidi 250 grams, Radix Achyranthis Bidentatae 200 grams, Fructus Cnidii 100 grams, Rhizoma Coptidis 50 grams, the Radix Paeoniae Alba 100 grams, JIANCAO 50 grams, Radix Arnebiae (Radix Lithospermi) 50 grams, the Cortex Eucommiae 100 grams, Herba Lycopodii 20 grams, the Rhizoma Atractylodis Macrocephalae 50 grams, Radix Curcumae 50 grams and Radix Codonopsis 20 grams, pulverize, cross 40 mesh sieves, add 100 liters, water, under reflux conditions heat 6 hours, filter, filtrate is made to be cooled to room temperature.
Clinical trial
All cases is totally 100 examples, is divided into treatment group 50 example, matched group 50 example.Treatment group max age 48 years old, minimal ages 15 years old, 32.5 years old mean age; Matched group max age 47 years old, minimal ages 17 years old, 31.6 years old mean age, two groups are compared there was no significant difference, P>0.05.The treatment group course of disease is the longest 7 years, the shortest 2 months, average 2.7 months; The matched group course of disease is the longest 7 years, the shortest 3 months, average 2.9 months, and two groups are compared there was no significant difference, P>0.05.
Diagnostic criteria
Traditional Chinese medical science Disease Diagnosis Standard: draft according to " new drug (Chinese medicine) guideline of clinical investigations ".(1) menorrhagia; Pass through at every turn and use sanitary towel more than 20 persons; (2) menostaxis, the time of at every turn passing through was more than 7 days persons.
Standards of Chinese Medical Syndrome Differentiation: draft according to " new drug (Chinese medicine) guideline of clinical investigations ".Syndrome of deficiency of spleen qi: menorrhagia or menostaxis incessantly dripping; Light red through color, thin menses; Inappetence; Fatigue and asthenia; Lower abdominal distention pendant; Large loose stool is thin; Profuse leukorrhea, color is white, odorless; Corpulent tongue or have tooth to print, body of the tongue is light red, white and thin fur; Moderate pulse is weak.
Inclusive criteria
All diagnosis meeting traditional Chinese medical science menorrhagia or menostaxis, dialectical genus deficiency of spleen-QI person.
Exclusion standard
In observation item, interrelated data is imperfect, lacks objectivity, comparability person; The medicine that application is similar to this product simultaneously, affect the treatment observer; The state of an illness is heavier, needs operator.
Treatment group uses the lotion prepared in embodiment, every day 2 times, each use 50 milliliters cleaning vaginas 5 minutes, continuous use 3 menstrual cycle.
Matched group each oral BUZHONG YIQI WAN (Beijing Tongrentang Technology Development Co.ltd. Pharmaceutical Factory) 9g, every day 3 times, continuous use 3 menstrual cycle.
Efficacy assessment standard
Cure: recover normal through the phase after treatment, other transference cures, after drug withdrawal, 3 menstrual cycle do not recur.Effective: have than minimizing about 1/3 before treatment through measuring it after treatment, menstrual period, he alleviated symptom within 7 days, and drug withdrawal 3 menstrual cycle recur again.Effective: reduce to some extent than before treatment through amount after treatment, or shorten to some extent before comparatively treating menstrual period, other symptoms make moderate progress.Invalid: after treatment through amount, menstrual period are without improvement.
The results are shown in Table 1.Result shows, the total effective rate for the treatment of group is 100%.The total effective rate of matched group is 60%.Two groups of efficacy results compare, and P<0.01, has significant differences, show that the curative effect for the treatment of group is better than matched group.
Table 1
| Group | Number of cases | Cure | Effective | Effectively | Invalid | Total effective rate (%) |
| Treatment group | 50 | 36 | 12 | 2 | 0 | 100 |
| Matched group | 50 | 8 | 12 | 10 | 20 | 60 |
Model case
Zhang, female, 25 years old, public institution staff, to our hospital on January 28th, 2013, private prosecution menostaxis reaches 10 days, passes through and uses sanitary towel 32, and menostaxis is more than, light red through color, thin menses, inappetence, fatigue and asthenia, moderate pulse is weak, leucorrhoea grow in quantity.Use the lotion prepared in embodiment, every day 2 times, each use 250 milliliters cleaning vaginas 5 minutes, continuous use 3 menstrual cycle.Recover normal through the phase after treatment, other transference cures, menstrual blood volume recovers normal, and within after drug withdrawal 3 months, carry out call-on back by phone weekly, patient's private prosecution symptom does not recur, and menstrual cycle is always normal.
King so-and-so, female, 36 years old, enterprise staff, to our hospital on March 16th, 2013, private prosecution menostaxis reaches 9 days, pass through and use sanitary towel 35, menostaxis is more than, light red through color, thin menses, lower abdominal distention pendant, large loose stool is thin, profuse leukorrhea, and color is white, and odorless, moderate pulse is weak.Use the lotion prepared in embodiment, every day 2 times, each use 250 milliliters cleaning vaginas 5 minutes, continuous use 3 menstrual cycle.Recover normal through the phase after treatment, other transference cures, menstrual blood volume recovers normal, and within after drug withdrawal 3 months, carry out call-on back by phone weekly, patient's private prosecution symptom does not recur, and menstrual cycle is always normal.
Close so-and-so, female, 41 years old, peasant, to our hospital on May 9th, 2013, private prosecution menostaxis reaches 10 days, pass through and use sanitary towel 31, menostaxis is more than, light red through color, thin menses, lower abdominal distention pendant, dizzy, fatigue and asthenia, large loose stool is thin, profuse leukorrhea, and color is white, and odorless, moderate pulse is weak.Use the lotion prepared in embodiment, every day 2 times, each use 250 milliliters cleaning vaginas 5 minutes, continuous use 3 menstrual cycle.Recover normal through the phase after treatment, other transference cures, menstrual blood volume recovers normal, and within after drug withdrawal 3 months, carry out call-on back by phone weekly, patient's private prosecution symptom does not recur, and menstrual cycle is always normal.
Claims (2)
1. the menorrheal pharmaceutical composition for the treatment of, it is characterized in that, it is made up by weight of following bulk drugs: Folium fici lacoris 50-100 part, Herba bromi japonici 50-100 part, Herba saniculae orthacanthae 50-100 part, Radix Angelicae Dahuricae 20-50 part, Radix Bupleuri 20-50 part, Semen Ziziphi Spinosae 20-50 part, Herba menyanthis 20-50 part, Radix Aconiti Lateralis Preparata 20-40 part, Fructus Arctii 20-50 part, Spica Prunellae 20-50 part, Herba Cleisostomatis scolopendrifolii 10-30 part, Radix Saposhnikoviae 20-50 part, Bulbus Lilii 20-50 part, Cortex celtis bungeanae (Cortex seu Caulis Celtis Bungeane) 20-40 part, Ramulus Cinnamomi 20-40 part, Rhizoma Atractylodis 10-30 part, Radix et Rhizoma Smilacis Ripariae 10-30 part, Fructus Ligustri Lucidi 20-40 part, Radix Achyranthis Bidentatae 10-30 part, Fructus Cnidii 1-30 part, Rhizoma Coptidis 1-20 part, Radix Paeoniae Alba 1-30 part, JIANCAO 1-10 part, Radix Arnebiae (Radix Lithospermi) 1-10 part, Cortex Eucommiae 1-30 part, Herba Lycopodii 1-10 part, Rhizoma Atractylodis Macrocephalae 1-10 part, Radix Curcumae 1-10 part and Radix Codonopsis 1-10 part.
2. the menorrheal pharmaceutical composition for the treatment of according to claim 1, it is characterized in that, it is made up by weight of following bulk drugs: Folium fici lacoris 55 parts, Herba bromi japonici 70 parts, Herba saniculae orthacanthae 60 parts, the Radix Angelicae Dahuricae 40 parts, Radix Bupleuri 35 parts, Semen Ziziphi Spinosae 50 parts, Herba menyanthis 30 parts, Radix Aconiti Lateralis Preparata 25 parts, Fructus Arctii 45 parts, Spica Prunellae 30 parts, Herba Cleisostomatis scolopendrifolii 20 parts, Radix Saposhnikoviae 40 parts, Bulbus Lilii 40 parts, Cortex celtis bungeanae (Cortex seu Caulis Celtis Bungeane) 30 parts, Ramulus Cinnamomi 25 parts, Rhizoma Atractylodis 15 parts, Radix et Rhizoma Smilacis Ripariae 15 parts, Fructus Ligustri Lucidi 25 parts, Radix Achyranthis Bidentatae 20 parts, Fructus Cnidii 10 parts, Rhizoma Coptidis 5 parts, the Radix Paeoniae Alba 10 parts, JIANCAO 5 parts, Radix Arnebiae (Radix Lithospermi) 5 parts, the Cortex Eucommiae 10 parts, Herba Lycopodii 2 parts, the Rhizoma Atractylodis Macrocephalae 5 parts, Radix Curcumae 5 parts and Radix Codonopsis 2 parts.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410108684.7A CN103830684B (en) | 2014-03-24 | 2014-03-24 | One treats menorrheal pharmaceutical composition and application thereof |
| CN201510578258.4A CN105106847B (en) | 2014-03-24 | 2014-03-24 | One treats menorrheal pharmaceutical composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410108684.7A CN103830684B (en) | 2014-03-24 | 2014-03-24 | One treats menorrheal pharmaceutical composition and application thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510578258.4A Division CN105106847B (en) | 2014-03-24 | 2014-03-24 | One treats menorrheal pharmaceutical composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103830684A CN103830684A (en) | 2014-06-04 |
| CN103830684B true CN103830684B (en) | 2016-02-03 |
Family
ID=50794786
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510578258.4A Expired - Fee Related CN105106847B (en) | 2014-03-24 | 2014-03-24 | One treats menorrheal pharmaceutical composition and application thereof |
| CN201410108684.7A Expired - Fee Related CN103830684B (en) | 2014-03-24 | 2014-03-24 | One treats menorrheal pharmaceutical composition and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510578258.4A Expired - Fee Related CN105106847B (en) | 2014-03-24 | 2014-03-24 | One treats menorrheal pharmaceutical composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105106847B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105796722A (en) * | 2016-04-09 | 2016-07-27 | 乔兴友 | Traditional Chinese medicine composition for treating spleen-qi deficiency type menoxenia after insertion of intrauterine device |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100360159C (en) * | 2004-07-05 | 2008-01-09 | 天津宏仁堂药业有限公司 | Kidney benefiting, Chong collateral reinforcing and menstruation regulating hemostat |
| CN101085116A (en) * | 2007-06-26 | 2007-12-12 | 北京艺信堂医药研究所 | Traditional Chinese medicine preparation for treating menorrhagia |
| CN101417064B (en) * | 2008-10-31 | 2011-03-23 | 江门德鑫制药有限公司 | Traditional Chinese medicine combination for treating gynecology blood disease and preparation method thereof |
| CN101843888B (en) * | 2010-06-30 | 2011-07-06 | 泰一和浦（北京）中医药研究院有限公司 | Novel Chinese medicinal composition for treating menorrhagia and a preparation method thereof |
| CN103330805B (en) * | 2013-06-27 | 2015-04-01 | 付海英 | Traditional Chinese medicine composition for treating menorrhagia |
-
2014
- 2014-03-24 CN CN201510578258.4A patent/CN105106847B/en not_active Expired - Fee Related
- 2014-03-24 CN CN201410108684.7A patent/CN103830684B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN105106847A (en) | 2015-12-02 |
| CN105106847B (en) | 2016-07-06 |
| CN103830684A (en) | 2014-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102614440B (en) | Multi-herb antibacterial liquid | |
| CN102872418B (en) | Medicine for treating pelvic inflammation | |
| CN102284050B (en) | Chinese medicine composition for treating infertility caused by cold uterus | |
| CN103432545A (en) | Medicament for allaying fever of child and preparation method thereof | |
| CN101797335A (en) | Chinese medicinal composition for treating functional uterine bleeding | |
| CN103356932B (en) | A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia | |
| CN103830684B (en) | One treats menorrheal pharmaceutical composition and application thereof | |
| CN105194584A (en) | Medicine for treating dysmenorrhea | |
| CN102727628B (en) | Chinese medicinal composition for treating functional constipation through hilum therapy | |
| CN103301368B (en) | Medicament for treating hyperactivity | |
| CN104147419A (en) | Traditional Chinese medicine composition for treating immune thrombocytopenia | |
| CN105521116A (en) | Traditional Chinese medicine for treating bacillary dysentery | |
| CN104162043A (en) | Traditional Chinese medicine used for treatment of allergic nodular cutaneous vasculitis | |
| CN104800675A (en) | Medicament for treating active ulcerative colitis | |
| CN104548048A (en) | Traditional Chinese medicine composition for treating rheumatic tendon and bone diseases | |
| CN104825610A (en) | Preparation method of pharmaceutical composition for treating chronic pelvic inflammatory disease | |
| CN103800844B (en) | A kind of pharmaceutical composition for the treatment of acute pancreatitis and preparation method thereof | |
| CN103536879A (en) | Pharmaceutical composition for treating diabetes mellitus and preparation method thereof | |
| CN103585471B (en) | Traditional Chinese medicine composition for treating thrombocytopenia | |
| CN102836346B (en) | Traditional Chinese medicine for treating lumbar disc herniation | |
| CN102327587B (en) | Traditional Chinese herbal medicine for curing chronic or intractable immune thrombocytopenia and preparation method of Traditional Chinese medicine preparation | |
| CN105232609A (en) | Traditional Chinese medicine combination treating functional dyspepsia | |
| CN105687488A (en) | Traditional Chinese medicine for treating climacteric syndromes | |
| CN104758663A (en) | External-use liniment used for varicosity and application thereof | |
| CN104606553B (en) | A kind of pharmaceutical composition for the treatment of hemopenia fever in puerperal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160203 Termination date: 20170324 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |